Angiotensin II Antagonists with Prolonged Duration of Action Possible Anti-Hypertensive Drugs

  • Emanuel Escher
Part of the Biochemical Endocrinology book series (BIOEND)


Hypertension and the renin-angiotensin system are closely related and neither one can be described or investigated without considering the other. On a molar basis, Angiotensin II (AT) is still the most potent vasopressor agent and is therefore a prime candidate for drug induced blood pressure regulation. The octapeptide AT of the sequence Asp-Arg-Val-Tyr-Ile-His-Pro-Phe is produced in the circulation and not by regulated secretion like other peptide hormones, e.g. Vasopressin or ACTH (1).


Angiotensin Converting Enzyme Intrinsic Activity Relative Affinity Rabbit Aorta Smooth Muscle Preparation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    M.B. Vallotton, The renin-angiotensin system, TIPS 8: 69 (1987).Google Scholar
  2. 2.
    S.A.M.A. Al-Merani, D.P. Brooks, B.J. Chapman and K.A. Munday, The half-lives of angiotensin II, angiotensin II-amide, angiotensin III, Sar1, Ala -angiotensin II and renin in the circulatory system of the rat, J. Physiol. 278: 471 (1978).PubMedGoogle Scholar
  3. 3.
    M.I. Phillips, J. Weyhenmeyer, D. Felix, D. Ganten and W.E. Hoffman, Evidence for an endogenous brain renin-angiotensin system, Federation Proc. 38: 2260 (1979).Google Scholar
  4. 4.
    M.A. Ondetti, B. Rubin, D.W. Cushman, Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents, Science 196: 441 (1977).PubMedCrossRefGoogle Scholar
  5. 5.
    C.S. McCaa, H.G. Langford, W.C. Cushman and R.E. McCaa, Response of arterial blood pressure, plasma renin activity and plasma aldosterone concentration to long-term administration of Captopril in patients with severe, treatment-resistant malignant hypertension, Clinical Science 57: 371s (1979).Google Scholar
  6. 6.
    M. Tree, M. Szelke, B. Leckie, B. Atrash, B. Donovan, A. Hallett, D.M. Jones, A.F. Lever, J.J. Morton, J. Sueiras-Diaz, P. Manhem, J.I.S. Robertson and D. Webb, Renin inhibitors: their use in understanding the role of angiotensin II as a pressor hormone, J. Cardiovasc. Pharmacol. 7: (Suppl.4) S49, 1985.PubMedCrossRefGoogle Scholar
  7. 7.
    C. Fessier, F. Sipos, G.S. Denning, D.T. Pals and F.D. Masucci, Angiotensin II antagonism. Structure-activity relationships of 8-substituted angiotensin II analogs, J. Med. Chem. 15: 1015 (1972).CrossRefGoogle Scholar
  8. 8.
    A. Aumelas, C. Sakarellos, K. Lintner, S. Fermandjian, M.C. Khosla, R.R. Smeby and F.M. Bumpus, Studies on angiotensin II and analogs: impact of substitution in position 8 on conformation and activity, Proc. Natl. Acad. Sci. 82: 1881 (1985).PubMedCrossRefGoogle Scholar
  9. 9.
    F.M. Bumpus, Mechanisms and sites of action of newer angiotensin agonists and antagonists in terms of activity and receptor, Federation Proc. 36: 2128 (1977).Google Scholar
  10. 10.
    R.L. Soffer and I. Sen, Angiotensin receptor is a desirable locus for physiologically specific inhibition of the renin-angiotensin system, J. Cardiovas. Pharmacol. 7: (Suppl. 4) S69 (1985).CrossRefGoogle Scholar
  11. 11.
    D. Regoli, W.K. Park and F. Rioux, Pharmacology of angiotensin, Pharmacol. Rev. 26: 69 (1974).Google Scholar
  12. 12.
    E.D. Frohlick, M.H. Maxwell, L. Baer, H. Gavras, J.W. Hollifield, L.R. Krakoff, M.D. Lifschitz, A. Logan, E. Poutasse, D.H.P. Streeten, A. Ochsner, Use of saralasin as a diagnostic test in hypertension, Arch. Int. Med. 142: 1437 (1982).CrossRefGoogle Scholar
  13. 13.
    J. St-Louis, D. Regoli, J. Barabé and W.K. Park, Myotropic actions of angiotensin and noradrenaline in strips of rabbit aortae, Can. J. Physiol. Pharmacol. 55: 1056 (1977).PubMedCrossRefGoogle Scholar
  14. 14.
    H. Glossmann, A.J. Baukal and K.J. Catt, Properties of angiotensin II receptors in the bovine and rat adrenal cortex, J. Biol. Chem. 249: 825 (1974).PubMedGoogle Scholar
  15. 15.
    G. Guillemette, G. Guillon, J. Marie, M.N. Balestre, E. Escher and S. Jard, High yield photoaffinity labeling of angiotensin II receptors, Molecular Pharmacology 30: 544 (1986).PubMedGoogle Scholar
  16. 16.
    O. Leukart, E. Escher, D. Regoli, and R. Schwyzer, Synthesis of angiotensins, bradykinins and substance P octapeptides in which the residues Phe and Tyr have been replaced with Car and of [Car, Leu]-enkephalin, Helv. Chim. Acta 62: 546 (1979).CrossRefGoogle Scholar
  17. 17.
    K.Q. Do, P. Thanei, M. Caviezel and R. Schwyzer, The synthesis of (S)-(+)-2-amino-3-(1-adamantyl)-propionic acid (L-(+)-adamantylalanine, Ada) as a fat or super analogue of leucine and phenylalanine, Helv. Chim. Acta 62: 956 (1979).CrossRefGoogle Scholar
  18. 18.
    E. Cuingnet, M. Dautrevaux, C. Sergheraert, A. Tartar, Synthesis and biological activity of metallocenic enkephalin analogs, Eur. J. Med. Chem. 17: 203 (1982).Google Scholar
  19. 19.
    J.C. Brunet, E. Cuingnet, H. Gras, P. Marcincal, A. Mocz, C. Sergheraert and A. Tartar, J. Organomet. Chem. 216: 73 (1981).CrossRefGoogle Scholar
  20. 20.
    E. Escher, G. Guillemette, O. Leukard and D. Regoli, Pharmacological properties of two analogues of angiotensin II containing carboranylalanine (Car), Eur. J. Pharmacol. 66: 267 (1980).PubMedCrossRefGoogle Scholar
  21. 21.
    A. Tartar, A. Demarly, C. Sergheaert, G. Frigon-Champagne and E. Escher. Metallocene angiotensin II analogues. Synthesis and biological activities, In: Peptides ′83, V. Hruby ed., Pierce Corp., Rockford, Ill. pp. 377 (1984).Google Scholar
  22. 22.
    E. Escher, T.M.D. Nguyen and D. Regoli, Photoaffinity labeling of the angiotensin II-receptor, Pharmacology of the labeling peptides in the dark, Can. J. Physiol. Pharmacol. 56: 956 (1978).PubMedCrossRefGoogle Scholar
  23. 23.
    R. Leduc, M. Bernier and E. Escher. Angiotensin II analogues I: Syntheses and incorporation of the halogenated amino acids (4′-I)phenylalanine, (3′,5′-Br -4′-CI)phenylalanine, (3′,4′,5′-Br3)phenylalanine, and (2′,3′,4′,5′,6′-Br5)-phenylalanine, Helv. Chim. Acta 66: 960 (1983).CrossRefGoogle Scholar
  24. 24.
    E. Escher, H. Mayhew, G. Guillemette, M. Bernier and D. Regoli, Tri-halogenated phenylalanine for tritium labeling of polypeptide hormones and for structure-activity studies. In Peptides, Proc. of the 6th American Peptide Symposium, E. Gross and J. Meienhofer ed., Pierce Chemical Company, Rockford, Ill. pp. 153 (1979).Google Scholar
  25. 25.
    J.J. Nestor, R. Tahilramani, T.L. Ho, G.I. McRae and R.H. Vickery, Luteinizing hormone-releasing hormone antagonists containing very hydrophobic amino acids, J. Med. Chem. 27: 1170, (1984).PubMedCrossRefGoogle Scholar
  26. 26.
    D.N. Chaturvedi, J.J. Knittel, V.J. Hruby, A.M. de L. Castrucci and M.E. Hadley, Synthesis and biological actions of highly potent and prolonged acting biotin-labeled melanotropins, J. Med. Chem. 27: 1406 (1984).PubMedCrossRefGoogle Scholar
  27. 27.
    J. Rudinger, The design of peptide hormone analogs. In Drug Design, E.J. Ariens, ed., Acad. Press, pp. 319–419 (1971).Google Scholar
  28. 28.
    W. McDonald, C. Wickre, S. Aumann, D. Ban and B. Moffitt, The sustained antihypertensive effect of chronic cerebroventricular infusion of angiotensin antagonist in spontaneously hypertensive rats, Endocrinology 107: 1305 (1980).PubMedCrossRefGoogle Scholar
  29. 29.
    J.F.E. Mann, E.L. Schiffrin, P.W. Schiller, W. Rascher, R. Boucher and J. Genest, Central actions and brain receptor binding of angiotensin II: Influence of sodium intake, Hypertension 2: 437 (1984).CrossRefGoogle Scholar
  30. 30.
    J.E. Rivier, J. Porter, C.L. Rivier, M. Perrin, A. Corrigan, W.A. Hook, R.P. Siraganian and W.W. Vale, New effective gonadotropin releasing hormone antagonists with minimal potency for histamine release in vitro, J. Med. Chem. 29: 1846 (1986).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • Emanuel Escher
    • 1
  1. 1.Department of Pharmacology, Faculty of MedicineUniversity of SherbrookeSherbrookeCanada

Personalised recommendations